This undated file photo shows the sign of South Korea’s pharmaceutical giant Celltrion Inc. (Image courtesy of Yonhap)
SEOUL, Dec. 9 (Korea Bizwire) — South Korea’s pharmaceutical giant Celltrion Inc. said Monday that it has received approval from Canadian health authorities for a biosimilar treatment for allergic asthma.
The company said that its biosimilar, Omlyclo, a version of Xolair, has been approved by Health Canada, adding that studies have demonstrated its equivalent performance and safety compared to the original.
The global market for Xolair, meanwhile, reached US$3.63 billion in 2023, with Canada accounting for $138 million, according to Celltrion.
“As Canada is considered one of the countries with biosimilar-friendly policies, the company plans to continue supplying high-quality pharmaceutical products to further solidify its presence in the market,” Celltrion said in a statement.
(Yonhap)
